World Muscle Society awards 2023 DRF prize

The World Muscle Society has once again awarded the Duchenne Research Fund prize at the annual WMS international congress, supporting a talented researcher in the Duchenne arena. The winner at the 28th congress in Charleston, South Carolina, USA, in October 2023 was...

FDA approves first gene therapy for Duchenne

It has been a busy time in the Duchenne arena. In the US, the FDA has granted accelerated approval for the gene therapy treatment SRP-9001. This is the first time a gene therapy for Duchenne has been approved anywhere in the world, and represents a very exciting step...

Catalysts Pharmaceuticals to distribute vamorolone in North America

Santhera Pharmaceuticals, which manufacturers vamorolone – the steroid alternative which the DRF was involved in funding at the Phase 1 stage – has announced it has licensed vamorolone to Catalyst Pharmaceuticals in North America. Catalyst Pharmaceuticals...

DRF highlights psychosocial research at parent information day

The Duchenne Research Fund was pleased to participate in Duchenne UK’s latest parent information day, held in March in central London. Dozens of families attended from all over the UK, and one even made the trip from Boston to hear about the latest research and...

See the smart suit that is changing children’s lives

On Rare Disease Day, watch Eli Crossley, son of our friend and Duchenne UK co-founder Emily, as he talks about – and demonstrates – the amazing technological developments that are being trialled for children with Duchenne muscular dystrophy. The ‘smart...

Psychosocial project now under way with DRF funding

28th February is Rare Disease Day. Duchenne muscular dystrophy may be a rare disease, but it can bring with it challenges which are all too familiar. There is an increased risk of mental health, emotional and behavioural needs in Duchenne muscular dystrophy patients,...

DRF co-founder raises £15,000 in first marathon

We are so proud of our co-founder, Doron Rosenfeld, who has completed his first ever marathon in 4 hours 43 minutes. Doron said: “I always promised I would never run a marathon… I never had the desire to run one, I never believed I could. But then, following...

Solid completes acquisition of AavantiBio

We are pleased to share that Solid Biosciences has completed its acquisition of gene therapy company AavantiBio, to create a genetic medicine company focused on neuromuscular and cardiac rare disease, with a continued, strong focus on Duchenne. At this pivotal moment...